Sign inCreate account

Report workspace tools

NCT03731845ACTIVE_NOT_RECRUITINGanonymous

Evaluation of Individual Sensitivity to the Gonadotoxicity of Chemotherapy in Young Patients With Breast Cancer

Sponsor

Source record

Assistance Publique - Hôpitaux de Paris

Phase

Source record

NA

Modality

AI-normalized

gene therapy

Target

AI-normalized

Breast Cancer

Indication / condition

AI-normalized

Breast Cancer

Intervention

Source record

Blood sample for genetic test, Blood sample for hormonal measurement, Ovarian ultrasound scan

Source & freshness

Source record

NCT ID

NCT03731845

Original source

ClinicalTrials.gov

Source last updated

Nov 20, 2025

Ingested at

May 30, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT03731845

Title

Evaluation of Individual Sensitivity to the Gonadotoxicity of Chemotherapy in Young Patients With Breast Cancer

Sponsor

Assistance Publique - Hôpitaux de Paris

Status

ACTIVE_NOT_RECRUITING

Phase

NA

Condition raw

Breast Cancer

Condition normalized

Breast Cancer

Modality raw

Breast Cancer

Modality normalized

gene therapy

Target raw

Breast Cancer

Target normalized

Breast Cancer

Interventions

Blood sample for genetic test, Blood sample for hormonal measurement, Ovarian ultrasound scan

Public preview

Source record

The ESIGON trial evaluates the genetic factors influencing ovarian reserve decline in young breast cancer survivors post-chemotherapy. With rising survival rates, understanding fertility preservation is crucial for improving quality of life in this demographic.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Evaluation of Individual Sensitivity to the Gonadotoxicity of Chemotherapy in Young Patients With Breast Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03731845

Status

ACTIVE_NOT_RECRUITING

Phase

NA

Sponsor

Assistance Publique - Hôpitaux de Paris

Executive brief

Investment-Ready Snapshot

The ESIGON trial evaluates the genetic factors influencing ovarian reserve decline in young breast cancer survivors post-chemotherapy. With rising survival rates, understanding fertility preservation is crucial for improving quality of life in this demographic.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 20, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03731845

Indication

Breast Cancer

Modality

gene therapy

Target

Breast Cancer

Intervention

Blood sample for genetic test, Blood sample for hormonal measurement, Ovarian ultrasound scan

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.